Description
- Contains 12 relevant, practice-oriented topics including theragnostics trials; neuroendocrine tumors: diagnostics; prostate-specific membrane antigen: diagnostics; theragnostics: post-therapy imaging; fibroblast-activation-protein inhibitors (FAPI) theragnostics; and more.- Provides in-depth clinical reviews on theragnostics, offering actionable insights for clinical practice.- Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.In this issue of PET Clinics, guest editors Drs. Andrei Iagaru and Heather A. Jacene bring their considerable expertise to the topic of Theragnostics. Top experts in the field discuss neuroendocrine tumors: beta-labeled peptides; prostate-specific membrane antigen: interpretation criteria, standardized reporting and the use of artificial intelligence; prostate cancer (gastrin-releasing peptide receptor); selective internal radiation therapy; future directions in theragnostics; and more.
Table of Contents
Alpha and Beta Radiation for TheragnosticsNeuroendocrine Tumors: DiagnosticsAlpha-emitter Peptide Receptor Radionuclide Therapy in Neuroendocrine TumorsProstate-specific Membrane Antigen: DiagnosticsProstate-specific Membrane Antigen: Interpretation Criteria, Standardized Reporting, and the Use of Machine LearningProstate-specific Membrane Antigen: Alpha-labeled RadiopharmaceuticalsProstate Cancer Radioligand Therapy: Beta-labeled RadiopharmaceuticalsGastrin Releasing Peptide Receptors-targeted PET Diagnostics and Radionuclide Therapy for Prostate Cancer Management: Preclinical and Clinical Developments of the Past 5 YearsTreatment Response Imaging in Prostate CancerHepatic Radioembolization: A Multistep Theragnostic Procedure
